ORIGINAL ARTICLE

Performance of routine syphilis serology in the Ethiopian cohort on HIV/AIDS

J W Dorigo-Zetsma, D Belewu, H Meless, E Sanders, R A Coutinho, A Schaap, D Wolday

Objective: To assess the performance of routine syphilis screening during 5 year follow up of Ethiopian factory workers, participating in a cohort study on HIV/AIDS.

Methods: Syphilis serology test results of factory workers, who each donated at least six blood samples were evaluated. Screening in 1997–8 had been performed by the Treponema pallidum particle agglutination (TPPA) assay and in 1999–2001 by the rapid plasma reagin (RPR) test. TPPA had been followed by RPR or RPR by TPPA, in case of a positive screening result. Samples of study subjects showing inconsistent sequential TPPA and/or RPR results were restested independently by three laboratory technicians.

Results: A total of 540 cohort participants (8.3% HIV positive at enrolment) donated 4376 blood samples (mean 8.3 per subject). From 93 of the 176 participants with at least one positive TPPA result during follow up, 152 samples were restested by RPR and/or TPPA. Based on the revised syphilis test results, the 540 cohort participants were classified as having no (70.5%), past (20.6%), prevalent (6.9%), or incident (2.0%) syphilis. The RPR screening test was difficult to interpret and yielded 8.2% biological false positive (BFP) RPR results, or 3.2% if weak positive results were excluded. There was no correlation between HIV infection and BFP RPR reactions. Sample mix-ups were detected in 1.2%.

Conclusion: Evaluation of routine syphilis screening as performed in a long term cohort study on HIV/AIDS in Ethiopia showed difficulties encountered in syphilis screening programmes such as a high percentage of BFP RPR, inconsistencies in interpretation of the RPR test, and sample mix ups. The findings stress the need to develop a syphilis screening assay that is easy to perform and interpret and to implement quality assurance programmes.

In many developing countries syphilis remains an important cause of morbidity and is associated, like other ulcerative sexual transmitted infections, with enhanced sexual transmission of HIV.1 Figures on prevalence and incidence of syphilis in several studies from sub-Saharan Africa are based on commonly used serological screening assays.2–6 However, the interpretation of non-treponemal and treponemal specific serological tests in a population where syphilis and HIV are endemic, is encountered with difficulty.7–9

The rapid plasma reagin (RPR) test is a non-treponemal serological test for syphilis widely used as a screening test in antenatal clinics and other health facilities in the developing world. The test is easy to perform, does not need advanced equipment, and is inexpensive. However, the RPR test may be difficult to interpret, it has shown both biological false positive (BFP) and false negative results and, particularly in HIV infected patients, the test has been known to generate BFP results.2 5 8 10 The limited specificity of the test can be ascribed to the aspecific nature of the cardiolipin antigen. In contrast, treponemal antibody tests such as the Treponema pallidum particle agglutination (TPPA) test and the fluorescent treponemal antibody (FTA) absorption test have a high specificity, but in HIV infected patients false negative reactions have been reported.11

The ongoing cohort study on HIV-1 infection incidence and progression was started in a factory in the suburbs of Addis Ababa, Ethiopia, in February 1997. Factory workers aged 18–44 years were enrolled, and participants gave consent to regular serological testing for both HIV and syphilis during follow up visits every 6 months. At each visit blood is drawn using EDTA vacutainer tubes (Becton and Dickinson, USA). Plasma is separated and tested for antibodies against HIV-1 by enzyme linked immunosorbent assay (ELISA, Vironostika HIV Uni-form II Plus O, Organon Teknika, Boxtel, Netherlands), with results confirmed by western blot (Genelabs Diagnostics Inc, Redwood City, CA, USA). Until July 1999, screening for syphilis was performed with a TPPA test (Serodia-TP, Fujirebio Inc, Tokyo, Japan), and in case of a positive TPPA result, the sample was tested for anti-cardiolipin antibodies with an RPR test (RPR Slide test, Biormerieux, Marcy l’Etoile, France). Since July 1999, because of the high percentage of TPPA positives in the study population, screening has been performed with RPR (RPR-Nosticon II, Organon Teknika, Boxtel, Netherlands) and followed by TPPA in case of a positive RPR. Tests are performed and interpreted according to instructions of the manufacturers. Plasma samples for RPR are tested undiluted, plasma samples for TPPA are tested in a 1:80 dilution.

Until July 1999, participants with positive TPPA on cohort enrolment were offered treatment for latent syphilis, three doses each of 2.4 million units of benzathine penicillin weekly, since reliable history of previous treatment is difficult.
to obtain. Sexual partners were also offered free treatment. Participants enrolled since July 1999 have been offered treatment for active syphilis (2.4 million units of benzathine penicillin, single dose) when a sample tested positive for both RPR and TPPA.

Blood samples are received daily at the ENARP laboratory in Addis Ababa, where they are registered. Within 1 week of arrival, plasma samples are tested using standard operating procedures, and test results are entered in the ENARP database. The laboratory participates in the external quality control programme for syphilis serology conducted bi-annually by the CDC, Atlanta, USA, with a score of >95% for RPR and 100% for TPPA during the past 5 years. After testing, plasma samples are stored at −80°C with a unique laboratory identification number to ensure efficient retrieval.

**Database screening, sample selection for retesting, and syphilis serodiagnosis**

For our study, we used the ENARP database to identify participants with six or more visits between their enrolment and December 2001. All eligible participants had been enrolled before July 1999, so at least one TPPA result was available for each of them. Based on syphilis results at their enrolment visit and follow up visits, participants were divided into three categories:

(a) no syphilis: syphilis tests on all visits negative

(b) biological false positive (BFP) syphilis tests: one or more weak positive or positive RPR tests, but negative TPPA

(c) at least one positive TPPA result, with or without positive RPR result.

Participants in categories (a) and (b) were interpreted as having no syphilis. For about half of the participants in category (c), it was difficult to interpret sequential syphilis test results because of inconsistencies. To establish a syphilis serodiagnosis for these participants, samples showing inconsistent sequential syphilis test results were retested in RPR (RPR-Nosticon II, Organon Teknika, Boxtel, Netherlands) and/or TPPA (Serodia-TP, Fujirebio Inc, Tokyo, Japan). Criteria for samples to be retested were a positive TPPA result among several negative TPPA results, or vice versa, a negative RPR result among several positive RPR results (with positive TPPA results), or a positive RPR result (with positive TPPA result) among several negative RPR results. Three laboratory technicians who were blinded to the previous results performed testing independently. Weak reactive RPR tests were interpreted as positive. A consensus test result was obtained if all three technicians reported the same findings. Consensus results were compared with the previously obtained results and were subsequently entered in the database. In case the three disagreed, the result from two technicians reporting the same result was entered.

Using the revised syphilis results, subjects in category (c) were classified as having past, prevalent, incident or no syphilis. Since these definitions were based on serology only, rather than combined serological and clinical findings, we did not use the standard terminology of primary, secondary, early, or late latent syphilis. Definitions were as follows:

past syphilis positive TPPA since enrolment without positive RPR, prevalent syphilis positive RPR and TPPA results since enrolment, incident syphilis sequential RPR seroconversion with or without TPPA seroconversion (in case TPPA was positive throughout), and no syphilis tests on all visits negative.

The incidence of syphilis was calculated per 100 person years of follow up, and confidence intervals were derived assuming a Poisson distribution of events. Cohort participants were divided according to their syphilis serostatus into age groups based on age at enrolment. The χ² test for trend with one degree of freedom was used to test increasing prevalence of past, prevalent, and incident syphilis infection with age.

For all samples with a positive TPPA screening result from enrolment until July 1999, the percentage of sample mix-ups was calculated, using the fact that TPPA remains positive for a long period, if not lifelong.

For all samples screened with RPR from July 1999 onwards, the percentage of BFP RPR test results was calculated. Association between HIV seropositivity and BFP RPR test results was tested by comparing HIV prevalence at enrolment among participants with BFP RPR test results and those with no serological evidence of syphilis using Pearson χ² test. Association between HIV seropositivity and syphilis was tested by comparing HIV prevalence at enrolment among participants with incident, prevalent, or past syphilis and those with no serological evidence of syphilis using Pearson χ² test. A p value of <0.05 was considered significant. Data were analysed using the Stata statistical package version 6.0 (Stata Statistical Software, Stata Corporation, College Station, TX, USA).

**RESULTS**

Out of 824 enrolled factory workers, 540 (66%) who had six or more cohort visits between February 1997 and December 2001, were selected for this study. Their mean age at enrolment was 35 years; 54% were males, 8.3% were HIV positive at enrolment, and 11.3% HIV positive at December 2001. They donated 4376 blood samples (mean 8.3 per subject). Table 1 shows how subjects were divided into categories (a), (b), and (c) according to their syphilis serological test results.

Category (c) included 176 subjects with at least one positive TPPA result during follow up. For 93 subjects (53%) in this category it was impossible to establish a syphilis serodiagnosis because of inconsistent sequential syphilis test results. A total of 152 samples from the 93 participants were selected for retesting by TPPA (n = 18), by RPR (n = 100), or by both tests (n = 34). Consensus, with all three technicians reporting the same result, was reached for TPPA in all 52 samples (100%). For RPR, the three technicians agreed in 99 of 134 samples (74%). In table 2 the performance of each technician is shown, with a positive RPR result being the least subject to inter-individual variation in interpretation.

After retesting, 17 subjects turned out to be completely negative for syphilis. Based on the revised results, the 540 cohort participants could be classified as having no (70.5%), past (20.6%), prevalent (6.9%), or incident (2.0%) syphilis (table 1). Syphilis incidence in the cohort was calculated to be 0.5% (95% CI: 0.2 to 0.7) per 100 person years.

From enrolment until July 1999, 785 samples were sequentially screened for TPPA and had a positive TPPA result. Among these, nine (1.2%) were definite sample mix-ups, being (confirmed) TPPA negative, among several positive TPPA results.

From July 1999 until December 2001, 2325 samples were sequentially screened for RPR. Among these, the percentage biological false positive RPR tests including both weak positive RPR (n = 115) and positive RPR samples (n = 75) was 8.2% (190/2325). Excluding the weak positive RPR samples, the false positive rate was 3.2%.

False positive RPR reactions were equally divided among the 170 participants in category (b), and no subject with chronic false positive reactions was seen. HIV seropositivity was not correlated with false positive RPR results, with 11/170 (6.5%) of such participants being HIV positive compared with 14/211 (6.6%) participants with no evidence of syphilis (p = 0.95). Excluding participants with weak positive RPR results there was still no correlation, with 6/70 (8.6%) participants with false positive RPR results being HIV positive.
increased with age (test for trend, p = 0.59).

Table 3 shows the age distribution related to syphilis serostatus. The prevalence of incident/prevalent/past syphilis showed an increasing trend with age (test for trend, p = 0.001).

HIV seropositivity was highly associated with serological evidence of syphilis, whether incident, prevalent, or past syphilis, with 28/159 (17.6%) of such participants being HIV positive compared with 33/381 (8.7%) participants with no evidence of syphilis (p = 0.003).

Among the 11 seroincident syphilis participants, two were HIV positive at enrolment and two seroconverted for HIV during the study. In one case, syphilis seroconversion and HIV seroconversion were detected in the same sample; in the other case, syphilis seroconversion was detected 6 months before HIV seroconversion.

DISCUSSION

Treponemal antigen based enzyme immunoassays (EIAs) have recently been introduced as an appropriate alternative to RPR/TPPA screening. In developing countries, however, where ELISA technology is not readily available in most places, the use of cardiolipin antigen based RPR tests combined with Treponema pallidum agglutination (TPPA) tests is still standard, and many facilities have only RPR or Veneral Disease Reference Laboratory (VDRL) tests. When positive findings can not be confirmed in treponemal specific antibody tests, overtreatment of syphilis may result because of BFP reactions in the cardiolipin antigen tests. In the present study, routine screening for syphilis was performed using both RPR and TPPA assays. With RPR, the BFP rate was as high as 8.2% but dropped to 3.2% if weak positive results were considered negative. This figure is higher than found in the general populations in Zimbabwe and Jamaica but agrees with findings in a recent study from rural communities in the Gambia. In the Gambian study, West et al calculated positive predictive values of the RPR test in relation to the prevalence of active syphilis in the community. Their findings suggest that in our setting, with a prevalence of active syphilis of 6.9%, the chance of someone with a positive test having active syphilis is less than 60%, and some overdiagnosis and overtreatment is bound to occur.

Although in some studies more BFP RPR results among HIV positive participants were reported, we did not find such correlation. However, populations in these studies (injecting drug users and STD clinic attendees) are not comparable with our healthy cohort participants, and as BFP RPR results are influenced by population characteristics, performance of the RPR test should be studied in the population where it is being used. Not all false positive RPR reactions in our study may be the result of biological factors, but it is possible also to be the result of limitations of the RPR test itself and subjective interpretation. This holds true particularly for the RPR reactions reported as weakly positive. However, upon excluding weak positive results, there was still no correlation between false positive RPR and HIV positivity. The BFP RPR reactions in our study population were all of transient nature and thus are more likely to be associated with acute intercurrent infections, such as relapsing fever, which is quite common in Ethiopia. The observation that BFP RPR reactions in HIV positive people might represent, in fact, false negative treponemal serology could also not be confirmed in our population, since these reactions were seen in one visit only. They occurred equally often in HIV positive and HIV negative participants (p = 0.59).
negative people, and none of them seroconverted for treponemal specific antibodies during follow up visits.

This study was based on syphilis serological test results obtained with RPR and TPPA, both tests having limitations as epidemiological tools. However, our longitudinal cohort was screened for syphilis every 6 months, giving us the unique opportunity to interpret syphilis serology over time. Retesting of samples from participants with inconsistent syphilis results obtained during follow up was necessary to enable proper interpretation. Apart from inter-individual variations in interpretation of the RPR test, retesting revealed sample mix-ups in 1.2% Reasons for sample mix-ups are difficult to retrieve, but at least in our setting handwritten labels and worksheets in the laboratory have been one reason, and handwriting was replaced by printed labels and electronically generated worksheets. Although usually not a major problem in epidemiological data analysis, sample mix-ups definitely do occur in clinical and laboratory practices, suggesting that quality assurance systems should be implemented to ensure reliable data for analysis.

Among our population in Ethiopia, we found a prevalence of past/prevalent/incident syphilis of 29.5%, which is high compared to prevalences found in other African studies, of past/prevalent/incident syphilis of 29.5%, which is high compared to prevalences found in other African studies, indicating that syphilis serological tests were influenced by specimen mix-up in clinical chemistry laboratories. Clinical Chemistry 1997;34:1124–5.

This study revealed a high percentage of BFP RPR results, inconsistent inter-individual interpretation of the non-treponemal RPR test, and sample mix ups. In populations like ours, the use of the RPR test as a single screening assay for syphilis is questionable. However, although both syphilis and HIV are common in this population, there was no indication that syphilis serological tests were influenced by HIV infection.

ACKNOWLEDGEMENTS

We thank A Beyene, D Tefera, and A Tafesse for technical assistance, NHTM Dukers and JPF Schelkens for comments on the manuscript, and LD Phillips for editorial review.

The Ethio-Netherlands AIDS Research Project (ENARP) is a collaborative effort of the Ethiopian Health and Nutrition Research Institute (EHNRI), Addis Ababa, the Municipal Health Service, Amsterdam, the Department of Human Retrovirology of the Academic Medical Centre (University of Amsterdam), and the Central Laboratory of the Netherlands Red Cross Blood Transfusion Service. ENARP is financially supported by the Dutch Ministry for Development Co-operation and the Ethiopian Ministry of Health.

CONTRIBUTORS

JWDZ designed the study, coordinated the laboratory testing, and drafted the report; DB coordinated the fieldwork, and syphilis treatment; HM supervised and contributed to the laboratory testing; ES and RC contributed to the study design and editing of the report; AS was responsible for data handling and analysis; DW contributed to the study design, coordination of laboratory testing, and edited the report.

AUTHORS’ AFFILIATIONS


R A Coutinho, Division of Public Health and Environment, Municipal Health Service, Amsterdam, Netherlands.

REFERENCES


www.stijournal.com

Downloaded from http://sti.bmj.com/ on April 2, 2017 - Published by group.bmj.com
Performance of routine syphilis serology in the Ethiopian cohort on HIV/AIDS

J W Dorigo-Zetsma, D Belewu, H Meless, E Sanders, R A Coutinho, A Schaap and D Wolday

Sex Transm Infect 2004 80: 96-99
doi: 10.1136/sti.2003.005827

Updated information and services can be found at:
http://sti.bmj.com/content/80/2/96

These include:

References
This article cites 18 articles, 9 of which you can access for free at:
http://sti.bmj.com/content/80/2/96#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Drugs: infectious diseases (3182)
- HIV/AIDS (2514)
- HIV infections (2514)
- Screening (epidemiology) (984)
- Screening (public health) (984)
- Syphilis (793)
- Epidemiologic studies (760)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/